Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Barcelona, Spain – Tuesday 2 September 2014: Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US. The findings suggest that caution may be needed when using digoxin in complex AF patients but further studies are needed to confirm the observations.
Dr Patel said: “In this subanalysis of the ROCKET AF trial we found that AF patients who took the drug digoxin had an increased risk of adverse cardiovascular events, including vascular death or sudden death.”
He added: “Digoxin, which works to strengthen heart contractions, is one of the oldest medications used in the treatment of patients with heart failure and it has also been used in patients who have AF. However the use of digoxin in AF patients has not been rigorously studied in randomised trials. We therefore conducted a retrospective subanalysis of the ROCKET AF trial to determine the effect of digoxin on the risk of death in patients with AF.”
The ROCKET AF trial was a double-blind trial conducted in 14 171 patients with nonvalvular AF who were at increased risk of stroke. The study took place at 1 178 sites in 45 countries. Patients were randomised to take either rivaroxaban or warfarin for anticoagulation. The trial found that in patients with AF, rivaroxaban was non-inferior to warfarin for the prevention of stroke or systemic embolism.In the current analysis, the researchers examined the risks of all cause mortality and cardiovascular mortality in 5 239 patients taking digoxin at the start of the study, compared to 8 932 patients who were not taking digoxin.The researchers found that the use of digoxin was associated with a 22% increased risk of death due to any cause and a 22% increased risk of death due to a cardiovascular event.
Dr Patel said: “Our analysis represents an important observation with digoxin use in patients with atrial fibrillation. Digoxin could potentially be harmful and we need randomised trials to determine whether it can be used patients with atrial fibrillation. Our findings suggest that doctors should proceed with caution when using this drug for complex AF patients.”
Dr Jeffrey Washam, a clinical pharmacist at the Duke Heart Center and first author of the abstract, said: “Despite being one of the oldest therapeutics in heart care, we still know very little regarding the risks and benefits of digoxin when used in patients with atrial fibrillation. In complex patients with atrial fibrillation, this analysis highlights the need for well-controlled studies to evaluate the efficacy and safety of digoxin.”Dr Patel concluded: “The results from this study should be confirmed in a prospective randomised trial.”
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2014The ESC Congress is currently the world's largest international congress in cardiovascular medicine. The spotlight of this year's event is “innovation and the heart”. ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
© 2017 European Society of Cardiology. All rights reserved